Tofacitinib: A Jak of All Trades
- PMID: 30625401
- PMCID: PMC6588476
- DOI: 10.1016/j.cgh.2018.12.044
Tofacitinib: A Jak of All Trades
Comment on
-
Tofacitinib for the Treatment of Pyoderma Gangrenosum.Clin Gastroenterol Hepatol. 2019 Apr;17(5):991-993. doi: 10.1016/j.cgh.2018.10.047. Epub 2018 Nov 4. Clin Gastroenterol Hepatol. 2019. PMID: 30404036
-
Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis.Clin Gastroenterol Hepatol. 2019 Apr;17(5):988-990.e1. doi: 10.1016/j.cgh.2018.11.022. Epub 2018 Nov 17. Clin Gastroenterol Hepatol. 2019. PMID: 30458248 Free PMC article.
-
Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.Clin Gastroenterol Hepatol. 2019 Jul;17(8):1541-1550. doi: 10.1016/j.cgh.2018.11.035. Epub 2018 Nov 23. Clin Gastroenterol Hepatol. 2019. PMID: 30476584 Clinical Trial.
References
-
- Dahlhamer JM, Zammitti EP, Ward BW, et al. Prevalence of Inflammatory Bowel Disease Among Adults Aged >/=18 Years - United States, 2015. MMWR Morb Mortal Wkly Rep 2016;65:1166–1169. - PubMed
-
- Beaugerie L, Kirchgesner J. Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2018. - PubMed
-
- Ma C, Panaccione R, Fedorak RN, et al. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clin Gastroenterol Hepatol 2018;16:637–647 e13. - PubMed
-
- Narula N, Alshahrani AA, Yuan Y, et al. Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2018. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources